Expression of ATP-binding Cassette Proteins Pgp, MRP1, and MRP3 in Malignant and Benign Ovarian Lesions

Česká verzia

Authors: I. Sedláková ¹; J. Laco ²; J. Tošner ¹; J. Špaček ¹
Authors place of work: Porodnická a gynekologická klinika LF UK a FN Hradec Králové ¹; Fingerlandův ústav patologie, LF UK a FN Hradec Králové ²
Published in the journal: Klin Onkol 2016; 29(5): 358-363
Category: Original Articles
doi: https://doi.org/10.14735/amko2016358

Summary

Background:
This study was designed to compare the expression of PgP (P-glycoprotein), MRP1 (multidrug related protein), and MRP3 in ovarian cancer patients, patients with benign ovarian tumors, and healthy women, and to evaluate the correlation between the expression of ATP-binding cassette proteins Pgp, MRP1, and MRP3 with stage, grade, and histological type.

Patients and Methods:
Tissue specimens from 212 women who underwent surgery at the Department of Obstetrics and Gynecology at University Hospital Hradec Králové were subjected to immunohistochemical staining for Pgp, MRP1, and MRP3.

Results:
The expression of Pgp and MRP1 was higher in ovarian tumor cells than in the cells lining the ovarian cyst. The lowest level of expression was found in normal ovarian tissue (p < 0.001). Histological subtype of epithelial ovarian cancer correlated with the expression of PgP, MRP1, and MRP3. The lowest level of Pgp and MRP1 expression was found in endometrioid ovarian cancers (p = 0.151; p = 0.013). Patients with advanced ovarian cancer (FIGO III + IV) had higher MRP1 expression than those with early stage ovarian cancer (median MRP1 FIGO I + II 80%; CI 60–100; FIGO III + IV 100%; CI 90–100; p = 0.100). An association was observed between MRP1 and tumor grade (p < 0.001).

Conclusion:
Pgp and MRP1 expression was higher in ovarian tumor cells than in cells lining the ovarian cyst. The lowest level of expression was found in normal ovarian tissue. ATP-binding cassette proteins play an important role in ovarian cancer pathogenesis.

Key words:
ATP-binding cassette proteins – ovarian cancer – P-glycoprotein (Pgp) – multidrug related protein 1 (MRP1) – multidrug related protein 3 (MRP3) – drug resistance

This work was supported by the Czech Ministry of Health NT 14107-3/2013.

The authors declare they have no potential confl icts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.

Submitted:
9. 11. 2015

Accepted:
30. 8. 2016

Zdroje

1. Cibula D, Petruželka L et al. Onkogynekologie. Praha: Grada Publishing 2009: 508.

2. Fruehauf PJ, Alberts DS. In vitro drug resistance versus chemosensitivity: two sides of different coins. J Clin Oncol 2005; 23 (15): 3641–3643.

3. Ozols RF, Schwartz PE, Eifel PJ. Ovarian cancer, fallopian tube carcinoma and peritoneal carcinoma. In: De Vita VT Jr, Hellman S, Rosenberg SA (eds). Cancer: principles and practice of oncology. 6th ed. Philadelphia: Lippincott-Raven 2001: 1597–1632.

4. Nosková V, Hajdúch M, Mihál V et al. Mechanismy mnohočetné lékové rezistence a jejich význam pro klinickou praxi I: typická MDR. Klin Onkol 2000; 13 (Speciál 2): 4–9.

5. Dean M, Fojo T, Bates S. Tumor stem cells and drug resistence in cancer. Nat Rev Cancer 2005; 5 (4): 275–284.

6. Scagliotti GV, Novello S, Selvaggi G. Multidrug resistence in non-small-cell lung cancer. Ann Oncol 1999; 10 (Suppl 5): 83–86.

7. Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002; 71: 537–592.

8. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE et al. P-glycoprotein: from genomics to mechanism. Oncogene 2003; 22 (47): 7468–7485.

9. Leslie EM, Deeley RG, Cole SP. Multidrug resistence proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 2005; 204 (3): 216–237.

10. Juliano RL, Ling V. A surface glykoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976; 455 (1): 152–162.

11. Thiebaut F, Tsuruo T, Hamada H et al. Expression of a multidrug-resistance gene product p-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84 (21): 7735–7738.

12. Kuwano M, Uchiumi T, Hayakawa H et al. The basic and clinical implications of ABC transporters, Y-box-binding protein-1 and angiogenesis-related factors in human malignancies. Cancer Sci 2003; 94 (1): 9–14.

13. Cole SP, Bhardwaj G, Gerlach JH et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992; 258 (5088): 1650–1654.

14. Evers R, Zaman GJ, van Deemter L et al. Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J Clin Invest 1996; 97 (5): 1211–1218.

15. Lorico A, Rappa G, Flavell RA et al. Double knockout of the MRP gene leeds to increased drug sensitivity in vitro. Cancer Res 1996; 56 (23): 5351–5355.

16. Allen JD, Brinkhuis RF, van Deemter L et al. Extensive contribution of the multidrug transporters P-glycoprotein and MRP1 to basal drug resistence. Cancer Res 2000; 60 (20): 5761–5766.

17. Slot AJ, Molinski SV, Cole SP. Mammalian multidrug-resistance proteins (MRPs). Esaays Biochem 2011; 50 (1): 179–207. doi: 10.1042/bse0500179.

18. Václavíková R, Hubáčková M, Kubala E et al. Exprese genu mnohočetné lékové rezistence 1 (MDR1) a její význam v rozvoji a terapii karcinomu prsu. Klin Onkol 2007; 20 (3): 253–259.

19. Goff BA, Paley JP, Greer EB et al. Evaluation of chemoresistance markers in woman with epithelial ovarian carcinoma. Gynecol Oncol 2001; 81 (1): 18–24.

20. Izquirerdo MA, van der Zee AG, Vermorken JB et al. Drug resistance-associated marker LRP for prediction of response to chemotherapy and prognosis in advanced ovarian carcinoma. J Natl Cancer Inst 1995; 87 (16): 1230–1237.

21. Sedláková I, Laco J, Tošner J et al. Proteiny rezistence LRP, Pgp, MRP1, MRP3 a MRP5 u pacientek s karcinomem ovaria. Ceska Gynekol 2013; 78 (6): 545–553.

22. Xing H, Wang S, Weng D et al. Knock-down of P-glycoprotein reverses taxol resistance in ovarian cancer multicellular spheroids. Oncol Rep 2007; 17 (1): 117–122.

23. Kamazawa S, Kigawa J, Kanamori Y et al. Multidrug resistance gene-1 is u useful predictor of paclitaxel-based chemotherapy for patients with ovarian cancer. Gynecol Oncol 2002; 86 (2): 171–176.

24. Scheffer GL, Kool M, Heijn M et al. Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprtoein with a panel of monoclonal antibodies. Cancer Res 2000; 60 (18): 5269–5277.

25. Odening KE, Rutz WL, Laufs S et al. Enhanced complement resistance in drug-selected P-glycoprotein expressing multi-drug-resistant ovarian carcinoma cells. Clin Exp Immunol 2008; 155 (2): 239–248. doi: 10.1111/j.1365- 2249.2008.03817.x.